Page last updated: 2024-08-07 16:10:39
D(1A) dopamine receptor
A D(1A) dopamine receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P21728]
Synonyms
Dopamine D1 receptor
Research
Bioassay Publications (122)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 5 (4.10) | 18.7374 |
| 1990's | 12 (9.84) | 18.2507 |
| 2000's | 43 (35.25) | 29.6817 |
| 2010's | 51 (41.80) | 24.3611 |
| 2020's | 11 (9.02) | 2.80 |
Compounds (163)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| sk&f 81297 | Homo sapiens (human) | Ki | 0.0150 | 1 | 1 |
| sk&f-38393 | Homo sapiens (human) | Ki | 0.3253 | 3 | 3 |
| 1-(3-chlorophenyl)biguanide | Homo sapiens (human) | Ki | 0.0170 | 1 | 1 |
| amiodarone | Homo sapiens (human) | IC50 | 9.1420 | 1 | 0 |
| amiodarone | Homo sapiens (human) | Ki | 4.5710 | 1 | 0 |
| amitriptyline | Homo sapiens (human) | IC50 | 0.3550 | 1 | 0 |
| amitriptyline | Homo sapiens (human) | Ki | 0.1335 | 2 | 1 |
| amoxapine | Homo sapiens (human) | IC50 | 0.3920 | 1 | 0 |
| amoxapine | Homo sapiens (human) | Ki | 0.1960 | 1 | 0 |
| astemizole | Homo sapiens (human) | IC50 | 4.0100 | 1 | 0 |
| astemizole | Homo sapiens (human) | Ki | 2.0050 | 1 | 0 |
| carvedilol | Homo sapiens (human) | IC50 | 1.4980 | 1 | 0 |
| carvedilol | Homo sapiens (human) | Ki | 0.7490 | 1 | 0 |
| celecoxib | Homo sapiens (human) | IC50 | 27.9940 | 1 | 0 |
| celecoxib | Homo sapiens (human) | Ki | 13.9970 | 1 | 0 |
| chlorpromazine | Homo sapiens (human) | IC50 | 0.2250 | 1 | 0 |
| chlorpromazine | Homo sapiens (human) | Ki | 0.1040 | 2 | 1 |
| ciglitazone | Homo sapiens (human) | IC50 | 19.7850 | 1 | 0 |
| ciglitazone | Homo sapiens (human) | Ki | 9.8930 | 1 | 0 |
| cisapride | Homo sapiens (human) | IC50 | 1.7000 | 1 | 1 |
| clomipramine | Homo sapiens (human) | IC50 | 1.1130 | 1 | 0 |
| clomipramine | Homo sapiens (human) | Ki | 0.5570 | 1 | 0 |
| clotrimazole | Homo sapiens (human) | IC50 | 9.0170 | 1 | 0 |
| clotrimazole | Homo sapiens (human) | Ki | 4.5080 | 1 | 0 |
| cyproheptadine | Homo sapiens (human) | IC50 | 0.1580 | 1 | 0 |
| cyproheptadine | Homo sapiens (human) | Ki | 0.0790 | 1 | 0 |
| disulfiram | Homo sapiens (human) | IC50 | 2.1580 | 1 | 0 |
| disulfiram | Homo sapiens (human) | Ki | 1.0790 | 1 | 0 |
| doxepin | Homo sapiens (human) | IC50 | 0.6880 | 1 | 0 |
| doxepin | Homo sapiens (human) | Ki | 0.3440 | 1 | 0 |
| droperidol | Homo sapiens (human) | IC50 | 1.0920 | 1 | 0 |
| droperidol | Homo sapiens (human) | Ki | 0.5460 | 1 | 0 |
| ebastine | Homo sapiens (human) | IC50 | 1.1929 | 1 | 0 |
| ebastine | Homo sapiens (human) | Ki | 0.5965 | 1 | 0 |
| econazole | Homo sapiens (human) | IC50 | 9.2250 | 1 | 0 |
| econazole | Homo sapiens (human) | Ki | 4.6120 | 1 | 0 |
| fenoldopam | Homo sapiens (human) | Ki | 0.0400 | 1 | 2 |
| fluphenazine | Homo sapiens (human) | IC50 | 0.0230 | 1 | 0 |
| fluphenazine | Homo sapiens (human) | Ki | 0.0950 | 2 | 1 |
| haloperidol | Homo sapiens (human) | IC50 | 0.0575 | 2 | 1 |
| haloperidol | Homo sapiens (human) | Ki | 0.0927 | 9 | 8 |
| haloprogin | Homo sapiens (human) | IC50 | 0.5630 | 1 | 0 |
| haloprogin | Homo sapiens (human) | Ki | 0.2820 | 1 | 0 |
| isoproterenol | Homo sapiens (human) | Ki | 50.0000 | 1 | 1 |
| ketotifen | Homo sapiens (human) | IC50 | 0.8720 | 1 | 0 |
| ketotifen | Homo sapiens (human) | Ki | 0.4360 | 1 | 0 |
| maprotiline | Homo sapiens (human) | IC50 | 0.3730 | 1 | 0 |
| maprotiline | Homo sapiens (human) | Ki | 0.2945 | 2 | 1 |
| mianserin | Homo sapiens (human) | IC50 | 0.5430 | 1 | 0 |
| mianserin | Homo sapiens (human) | Ki | 0.2710 | 1 | 0 |
| miconazole | Homo sapiens (human) | IC50 | 6.2470 | 1 | 0 |
| miconazole | Homo sapiens (human) | Ki | 3.1240 | 1 | 0 |
| nortriptyline | Homo sapiens (human) | IC50 | 0.5390 | 1 | 0 |
| nortriptyline | Homo sapiens (human) | Ki | 0.2690 | 1 | 0 |
| phenyl biguanide | Homo sapiens (human) | Ki | 1.2000 | 1 | 1 |
| prochlorperazine | Homo sapiens (human) | IC50 | 0.1550 | 1 | 0 |
| prochlorperazine | Homo sapiens (human) | Ki | 0.0780 | 1 | 0 |
| promazine | Homo sapiens (human) | IC50 | 2.4640 | 1 | 0 |
| promazine | Homo sapiens (human) | Ki | 1.2320 | 1 | 0 |
| promethazine | Homo sapiens (human) | IC50 | 2.7440 | 1 | 0 |
| promethazine | Homo sapiens (human) | Ki | 1.3720 | 1 | 0 |
| propranolol | Homo sapiens (human) | IC50 | 5.0119 | 1 | 1 |
| quetiapine | Homo sapiens (human) | IC50 | 0.4293 | 1 | 0 |
| quetiapine | Homo sapiens (human) | Ki | 1.5361 | 4 | 3 |
| quipazine | Homo sapiens (human) | Ki | 0.0018 | 1 | 1 |
| 6-nitroquipazine | Homo sapiens (human) | Ki | 0.0580 | 1 | 1 |
| 7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol | Homo sapiens (human) | IC50 | 0.2802 | 4 | 4 |
| 7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol | Homo sapiens (human) | Ki | 0.0014 | 2 | 2 |
| raloxifene | Homo sapiens (human) | IC50 | 3.8640 | 1 | 0 |
| raloxifene | Homo sapiens (human) | Ki | 1.9320 | 1 | 0 |
| rbi 257 | Homo sapiens (human) | Ki | 2.8300 | 1 | 1 |
| risperidone | Homo sapiens (human) | IC50 | 0.4790 | 1 | 0 |
| risperidone | Homo sapiens (human) | Ki | 0.3218 | 5 | 4 |
| spiperone | Homo sapiens (human) | Ki | 0.0008 | 1 | 2 |
| terfenadine | Homo sapiens (human) | IC50 | 2.6730 | 1 | 0 |
| terfenadine | Homo sapiens (human) | Ki | 1.3370 | 1 | 0 |
| thioridazine | Homo sapiens (human) | IC50 | 0.1940 | 1 | 0 |
| thioridazine | Homo sapiens (human) | Ki | 0.0970 | 1 | 0 |
| tyramine | Homo sapiens (human) | Ki | 390.0000 | 1 | 2 |
| zotepine | Homo sapiens (human) | Ki | 0.0565 | 2 | 2 |
| apomorphine | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| apomorphine | Homo sapiens (human) | Ki | 0.3266 | 8 | 8 |
| phenyltoloxamine | Homo sapiens (human) | Ki | 0.3430 | 1 | 1 |
| ergotamine | Homo sapiens (human) | IC50 | 1.7280 | 1 | 0 |
| ergotamine | Homo sapiens (human) | Ki | 0.8640 | 1 | 0 |
| methylergonovine | Homo sapiens (human) | IC50 | 1.0770 | 1 | 0 |
| methylergonovine | Homo sapiens (human) | Ki | 0.5390 | 1 | 0 |
| dibenzothiazyl disulfide | Homo sapiens (human) | IC50 | 1.1890 | 1 | 0 |
| dibenzothiazyl disulfide | Homo sapiens (human) | Ki | 0.5950 | 1 | 0 |
| indopan | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| methysergide | Homo sapiens (human) | IC50 | 0.9430 | 1 | 0 |
| methysergide | Homo sapiens (human) | Ki | 0.4720 | 1 | 0 |
| dihydroergotamine | Homo sapiens (human) | IC50 | 2.3950 | 1 | 0 |
| dihydroergotamine | Homo sapiens (human) | Ki | 1.1970 | 1 | 0 |
| gentian violet | Homo sapiens (human) | IC50 | 3.1020 | 1 | 0 |
| gentian violet | Homo sapiens (human) | Ki | 1.5510 | 1 | 0 |
| 1-naphthylisothiocyanate | Homo sapiens (human) | IC50 | 27.5760 | 1 | 0 |
| 1-naphthylisothiocyanate | Homo sapiens (human) | Ki | 13.7880 | 1 | 0 |
| 3-tyramine | Homo sapiens (human) | Ki | 48.0000 | 1 | 2 |
| n-methyllaurotetanine | Homo sapiens (human) | Ki | 0.3730 | 1 | 1 |
| canadine, (s)-isomer | Homo sapiens (human) | Ki | 0.0573 | 2 | 2 |
| clemastine | Homo sapiens (human) | IC50 | 1.5350 | 1 | 0 |
| clemastine | Homo sapiens (human) | Ki | 0.7670 | 1 | 0 |
| danazol | Homo sapiens (human) | IC50 | 20.4490 | 1 | 0 |
| danazol | Homo sapiens (human) | Ki | 10.2250 | 1 | 0 |
| metergoline | Homo sapiens (human) | IC50 | 0.0740 | 1 | 0 |
| metergoline | Homo sapiens (human) | Ki | 0.0370 | 1 | 0 |
| lisuride | Homo sapiens (human) | IC50 | 0.1730 | 1 | 0 |
| lisuride | Homo sapiens (human) | Ki | 0.0800 | 2 | 2 |
| bromocriptine | Homo sapiens (human) | IC50 | 2.8890 | 1 | 0 |
| bromocriptine | Homo sapiens (human) | Ki | 1.4440 | 1 | 0 |
| penfluridol | Homo sapiens (human) | Ki | 0.1470 | 1 | 1 |
| butaclamol | Homo sapiens (human) | Ki | 0.0032 | 4 | 4 |
| butaclamol | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| butaclamol | Homo sapiens (human) | Ki | 0.0028 | 1 | 1 |
| pergolide | Homo sapiens (human) | IC50 | 0.6790 | 1 | 0 |
| pergolide | Homo sapiens (human) | Ki | 1.4597 | 2 | 2 |
| quinpirole | Homo sapiens (human) | Ki | 166.2976 | 6 | 7 |
| sertindole | Homo sapiens (human) | Ki | 0.2100 | 1 | 1 |
| aripiprazole | Homo sapiens (human) | Ki | 0.5890 | 5 | 6 |
| ziprasidone | Homo sapiens (human) | Ki | 0.1565 | 3 | 3 |
| nelfinavir | Homo sapiens (human) | IC50 | 12.9350 | 1 | 0 |
| nelfinavir | Homo sapiens (human) | Ki | 6.4670 | 1 | 0 |
| tetrahydropalmatine | Homo sapiens (human) | IC50 | 1.6300 | 1 | 1 |
| tetrahydropalmatine | Homo sapiens (human) | Ki | 0.1920 | 2 | 2 |
| ergocornine | Homo sapiens (human) | IC50 | 0.2940 | 1 | 0 |
| ergocornine | Homo sapiens (human) | Ki | 0.1470 | 1 | 0 |
| 1,2,3,4,6,7,12,12b-octahydroindolo(2,3-a)quinolizine | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| gr 127935 | Homo sapiens (human) | Ki | 10.0000 | 2 | 2 |
| ecopipam | Homo sapiens (human) | Ki | 0.0014 | 5 | 5 |
| pd 128907 | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
| pramipexole | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| 2-(n,n-dimethylamino)-6,7-dihydroxytetralin | Homo sapiens (human) | Ki | 5.4000 | 1 | 2 |
| nnc 112 | Homo sapiens (human) | Ki | 0.0060 | 1 | 1 |
| 2-methoxy-n-n-propylnorapomorphine | Homo sapiens (human) | Ki | 2.5040 | 2 | 2 |
| sr 57227a | Homo sapiens (human) | Ki | 0.1030 | 1 | 1 |
| sc 53116 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| sc 53116 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| sonepiprazole | Homo sapiens (human) | Ki | 8.3780 | 1 | 1 |
| sk&f 83959 | Homo sapiens (human) | Ki | 0.0016 | 2 | 2 |
| l 741626 | Homo sapiens (human) | Ki | 0.7220 | 1 | 1 |
| alpha-ergocryptine | Homo sapiens (human) | IC50 | 0.4030 | 1 | 0 |
| alpha-ergocryptine | Homo sapiens (human) | Ki | 0.2020 | 1 | 0 |
| sk&f-38393 | Homo sapiens (human) | Ki | 0.0130 | 1 | 2 |
| chloroethylnorapomorphine | Homo sapiens (human) | IC50 | 8.0000 | 1 | 1 |
| harmalan | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| corydalmine | Homo sapiens (human) | IC50 | 21.2700 | 1 | 1 |
| corydalmine | Homo sapiens (human) | Ki | 0.0785 | 2 | 2 |
| n-n-propylnorapomorphine | Homo sapiens (human) | Ki | 0.8778 | 3 | 4 |
| n-demethyllysergic acid diethylamide | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| nantenine, (+-)-isomer | Homo sapiens (human) | Ki | 0.8950 | 1 | 1 |
| maduramicin | Homo sapiens (human) | IC50 | 2.9080 | 1 | 0 |
| maduramicin | Homo sapiens (human) | Ki | 1.4540 | 1 | 0 |
| 1-methyl-6-methoxy-dihydro-beta-carboline | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| discretamine | Homo sapiens (human) | Ki | 0.0220 | 1 | 1 |
| tetrahydrocolumbamine | Homo sapiens (human) | Ki | 0.0054 | 2 | 2 |
| terconazole | Homo sapiens (human) | IC50 | 25.4800 | 1 | 0 |
| terconazole | Homo sapiens (human) | Ki | 12.7400 | 1 | 0 |
| canadine, (r)-isomer | Homo sapiens (human) | Ki | 5.0000 | 1 | 1 |
| ergonovine | Homo sapiens (human) | IC50 | 5.9010 | 1 | 0 |
| ergonovine | Homo sapiens (human) | Ki | 2.9500 | 1 | 0 |
| dihydroergocristine monomesylate | Homo sapiens (human) | IC50 | 1.1790 | 1 | 0 |
| dihydroergocristine monomesylate | Homo sapiens (human) | Ki | 0.5890 | 1 | 0 |
| diethylstilbestrol | Homo sapiens (human) | IC50 | 7.7630 | 1 | 0 |
| diethylstilbestrol | Homo sapiens (human) | Ki | 3.8820 | 1 | 0 |
| cannabidiol | Homo sapiens (human) | Ki | 2.7000 | 1 | 1 |
| chlorprothixene | Homo sapiens (human) | Ki | 0.0180 | 1 | 1 |
| flunarizine | Homo sapiens (human) | IC50 | 3.8740 | 1 | 0 |
| flunarizine | Homo sapiens (human) | Ki | 1.9370 | 1 | 0 |
| tamoxifen | Homo sapiens (human) | IC50 | 8.5020 | 1 | 0 |
| tamoxifen | Homo sapiens (human) | Ki | 4.2510 | 1 | 0 |
| sch 23390 | Homo sapiens (human) | IC50 | 0.0461 | 10 | 12 |
| sch 23390 | Homo sapiens (human) | Ki | 0.0024 | 12 | 13 |
| bp 897 | Homo sapiens (human) | Ki | 0.7600 | 2 | 2 |
| n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| sb 408124 | Homo sapiens (human) | Ki | 1.7800 | 1 | 1 |
| le 300 | Homo sapiens (human) | Ki | 0.0160 | 8 | 9 |
| harmine | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| l 745870 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| pd 128907 | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
| sb 271046 | Homo sapiens (human) | Ki | 0.1200 | 1 | 1 |
| sulindac sulfide | Homo sapiens (human) | IC50 | 27.8220 | 1 | 0 |
| sulindac sulfide | Homo sapiens (human) | Ki | 13.9110 | 1 | 0 |
| bay 11-7085 | Homo sapiens (human) | IC50 | 4.4120 | 1 | 0 |
| bay 11-7085 | Homo sapiens (human) | Ki | 2.2060 | 1 | 0 |
| oxiconazole | Homo sapiens (human) | IC50 | 4.1361 | 1 | 0 |
| oxiconazole | Homo sapiens (human) | Ki | 2.0680 | 1 | 0 |
| a 77636 | Homo sapiens (human) | Ki | 0.0210 | 1 | 1 |
| dihydrexidine | Homo sapiens (human) | Ki | 0.4180 | 5 | 6 |
| sk&f-38393 | Homo sapiens (human) | Ki | 0.1292 | 5 | 6 |
| stepholidine | Homo sapiens (human) | IC50 | 0.0123 | 1 | 1 |
| stepholidine | Homo sapiens (human) | Ki | 0.0067 | 5 | 5 |
| 2-propyl-4,5,5a,6,7,11b-hexahydro-3-thia-5-azacyclopent-1-ena(c)phenanthrene-9,10-diol | Homo sapiens (human) | Ki | 0.0490 | 2 | 2 |
| yf 476 | Homo sapiens (human) | Ki | 0.0288 | 1 | 1 |
| fauc 346 | Homo sapiens (human) | Ki | 0.7350 | 2 | 2 |
| ngb 2904 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| pnu 96415e | Homo sapiens (human) | Ki | 0.4110 | 1 | 1 |
| mk 936 | Homo sapiens (human) | IC50 | 6.1190 | 1 | 0 |
| mk 936 | Homo sapiens (human) | Ki | 3.0600 | 1 | 0 |
| 4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| fauc 365 | Homo sapiens (human) | Ki | 4.9975 | 2 | 2 |
| 11-hydroxy-n-(n-propyl)noraporphine hydrochloride, (r)-isomer | Homo sapiens (human) | Ki | 4.7817 | 3 | 3 |
| fauc 213 | Homo sapiens (human) | Ki | 5.5000 | 1 | 1 |
| m-chlorophenylguanidine | Homo sapiens (human) | Ki | 0.0350 | 1 | 1 |
| fauc 113 | Homo sapiens (human) | Ki | 12.0000 | 1 | 1 |
| (5R)-9-bromo-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol | Homo sapiens (human) | Ki | 0.0030 | 1 | 2 |
| cariprazine | Homo sapiens (human) | Ki | 2.7506 | 3 | 4 |
| naphyrone | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| naluzotan | Homo sapiens (human) | Ki | 2.0000 | 1 | 1 |
| le 404 | Homo sapiens (human) | Ki | 0.0006 | 5 | 5 |
| N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide | Homo sapiens (human) | Ki | 0.0012 | 1 | 1 |
| a 803467 | Homo sapiens (human) | IC50 | 4.5000 | 2 | 2 |
| sp 203 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| defactinib | Homo sapiens (human) | Ki | 10.0000 | 2 | 0 |
| nitd 609 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| n,n-diallyl-5-methoxytryptamine | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| 3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| clozapine | Homo sapiens (human) | IC50 | 0.1070 | 1 | 0 |
| clozapine | Homo sapiens (human) | Ki | 0.1342 | 12 | 11 |
| olanzapine | Homo sapiens (human) | IC50 | 0.0720 | 1 | 0 |
| olanzapine | Homo sapiens (human) | Ki | 0.0745 | 6 | 5 |
| norclozapine | Homo sapiens (human) | Ki | 0.0800 | 1 | 1 |
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 4-hydroxybenzoic acid | Homo sapiens (human) | EC50 | 0.0011 | 1 | 1 |
| sk&f 81297 | Homo sapiens (human) | EC50 | 3.2882 | 3 | 3 |
| sk&f 82958 | Homo sapiens (human) | EC50 | 0.0014 | 2 | 2 |
| sk&f 77434 | Homo sapiens (human) | EC50 | 5.0005 | 2 | 2 |
| sk&f-38393 | Homo sapiens (human) | EC50 | 1.4484 | 8 | 8 |
| fenoldopam | Homo sapiens (human) | EC50 | 0.0172 | 2 | 2 |
| fenoldopam | Homo sapiens (human) | Kd | 0.0280 | 1 | 1 |
| propranolol | Homo sapiens (human) | EC50 | 5.0119 | 1 | 1 |
| ropinirole | Homo sapiens (human) | EC50 | 0.1000 | 1 | 2 |
| apomorphine | Homo sapiens (human) | EC50 | 0.1846 | 4 | 6 |
| apomorphine | Homo sapiens (human) | Kd | 0.6800 | 1 | 1 |
| n 0437, (-)-isomer | Homo sapiens (human) | EC50 | 0.0280 | 1 | 1 |
| dopamine hydrochloride | Homo sapiens (human) | EC50 | 0.0370 | 1 | 1 |
| pramipexole | Homo sapiens (human) | EC50 | 10.0000 | 1 | 1 |
| 2-(n,n-dimethylamino)-6,7-dihydroxytetralin | Homo sapiens (human) | Kd | 4.6000 | 1 | 1 |
| sk&f 83959 | Homo sapiens (human) | EC50 | 5.0001 | 2 | 2 |
| 10,11-methylenedioxy-n-propylnoraporphine | Homo sapiens (human) | EC50 | 1.3352 | 2 | 4 |
| sk&f 89124 | Homo sapiens (human) | EC50 | 0.0018 | 1 | 2 |
| corydalmine | Homo sapiens (human) | EC50 | 1.3500 | 1 | 1 |
| n-n-propylnorapomorphine | Homo sapiens (human) | EC50 | 0.9371 | 2 | 4 |
| n-n-propylnorapomorphine | Homo sapiens (human) | Kd | 1.8160 | 1 | 1 |
| sk&f 75670 | Homo sapiens (human) | EC50 | 5.0002 | 2 | 2 |
| a 77636 | Homo sapiens (human) | EC50 | 0.0030 | 1 | 1 |
| dihydrexidine | Homo sapiens (human) | EC50 | 0.0136 | 4 | 4 |
| sk&f-38393 | Homo sapiens (human) | EC50 | 0.0445 | 2 | 2 |
| sk&f-38393 | Homo sapiens (human) | Kd | 0.1500 | 1 | 1 |
| stepholidine | Homo sapiens (human) | EC50 | 0.0230 | 1 | 1 |
| 2-propyl-4,5,5a,6,7,11b-hexahydro-3-thia-5-azacyclopent-1-ena(c)phenanthrene-9,10-diol | Homo sapiens (human) | EC50 | 0.0090 | 2 | 2 |
| (5R)-9-bromo-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol | Homo sapiens (human) | Kd | 0.3840 | 1 | 1 |
Drugs with Other Measurements
[no title available]Journal of medicinal chemistry, , 05-23, Volume: 62, Issue:10, 2019
Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists.ACS medicinal chemistry letters, , May-09, Volume: 10, Issue:5, 2019
Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.Bioorganic & medicinal chemistry, , 05-15, Volume: 27, Issue:10, 2019
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy.Chemical biology & drug design, , Volume: 88, Issue:4, 2016
Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.Bioorganic & medicinal chemistry, , Nov-01, Volume: 22, Issue:21, 2014
Structural manipulation on the catecholic fragment of dopamine D(1) receptor agonist 1-phenyl-N-methyl-benzazepines.European journal of medicinal chemistry, , Oct-06, Volume: 85, 2014
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.Bioorganic & medicinal chemistry, , Aug-01, Volume: 20, Issue:15, 2012
'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.Bioorganic & medicinal chemistry, , Jul-15, Volume: 17, Issue:14, 2009
Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 19, Issue:2, 2009
Synthesis and evaluation of novel alkylpiperazines as potential dopamine antagonists.Journal of medicinal chemistry, , Volume: 24, Issue:6, 1981
[no title available],
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
Further evaluation of the tropane analogs of haloperidol.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 24, Issue:17, 2014
Synopsis of some recent tactical application of bioisosteres in drug design.Journal of medicinal chemistry, , Apr-28, Volume: 54, Issue:8, 2011
Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 19, Issue:21, 2009
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity.Journal of medicinal chemistry, , Aug-12, Volume: 47, Issue:17, 2004
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.Journal of medicinal chemistry, , Jul-05, Volume: 39, Issue:14, 1996
Aporphines. 58. N-(2-chloroethyl) [8,9-2H]norapomorphine, an irreversible ligand for dopamine receptors: synthesis and application.Journal of medicinal chemistry, , Volume: 27, Issue:6, 1984
Synthesis and evaluation of novel alkylpiperazines as potential dopamine antagonists.Journal of medicinal chemistry, , Volume: 24, Issue:6, 1981
[no title available],
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
[no title available],
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHBioorganic & medicinal chemistry, , 01-15, Volume: 25, Issue:2, 2017
Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy.Chemical biology & drug design, , Volume: 88, Issue:4, 2016
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.Bioorganic & medicinal chemistry, , Apr-15, Volume: 24, Issue:8, 2016
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013
Return of DJournal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017
Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 19, Issue:21, 2009
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
[no title available],
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Identification of C10 nitrogen-containing aporphines with dopamine DBioorganic & medicinal chemistry letters, , 04-15, Volume: 30, Issue:8, 2020
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.ACS medicinal chemistry letters, , Mar-12, Volume: 11, Issue:3, 2020
1-substituted apomorphines as potent dopamine agonists.Bioorganic & medicinal chemistry, , Jul-15, Volume: 21, Issue:14, 2013
Chemoenzymatic synthesis and evaluation of 3-azabicyclo[3.2.0]heptane derivatives as dopaminergic ligands.European journal of medicinal chemistry, , Volume: 55, 2012
New 2-thioether-substituted apomorphines as potent and selective dopamine D₂ receptor agonists.European journal of medicinal chemistry, , Volume: 46, Issue:7, 2011
Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 ReceptorsACS medicinal chemistry letters, , Mar-10, Volume: 2, Issue:3, 2011
N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists.Bioorganic & medicinal chemistry, , Jul-01, Volume: 17, Issue:13, 2009
Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.Bioorganic & medicinal chemistry, , Jul-15, Volume: 16, Issue:14, 2008
A novel synthesis and pharmacological evaluation of a potential dopamine D1/D2 agonist: 1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
Synthesis and dopaminergic activity of (R)- and (S)-4-hydroxy-2-(di-n-propylamino)indan.Journal of medicinal chemistry, , Volume: 28, Issue:4, 1985
Aporphines. 58. N-(2-chloroethyl) [8,9-2H]norapomorphine, an irreversible ligand for dopamine receptors: synthesis and application.Journal of medicinal chemistry, , Volume: 27, Issue:6, 1984
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors.Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013
Identification of C10 nitrogen-containing aporphines with dopamine DBioorganic & medicinal chemistry letters, , 04-15, Volume: 30, Issue:8, 2020
Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HTBioorganic & medicinal chemistry, , 08-01, Volume: 28, Issue:15, 2020
Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.Bioorganic & medicinal chemistry letters, , 08-15, Volume: 30, Issue:16, 2020
Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity.Bioorganic & medicinal chemistry, , May-01, Volume: 24, Issue:9, 2016
New tetrahydroisoquinoline-based DBioorganic & medicinal chemistry letters, , 06-15, Volume: 42, 2021
Aporphines. 58. N-(2-chloroethyl) [8,9-2H]norapomorphine, an irreversible ligand for dopamine receptors: synthesis and application.Journal of medicinal chemistry, , Volume: 27, Issue:6, 1984
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.Bioorganic & medicinal chemistry, , 06-15, Volume: 24, Issue:12, 2016
Molecular determinants of biased agonism at the dopamine D₂ receptor.Journal of medicinal chemistry, , Mar-26, Volume: 58, Issue:6, 2015
Functionally selective dopamine D₂, D₃ receptor partial agonists.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.Journal of medicinal chemistry, , Sep-08, Volume: 48, Issue:18, 2005
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
2-Phenylcyclopropylmethylamine Derivatives as Dopamine DJournal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased DJournal of medicinal chemistry, , 06-08, Volume: 60, Issue:11, 2017
Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.Journal of medicinal chemistry, , 04-13, Volume: 60, Issue:7, 2017
β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.Bioorganic & medicinal chemistry, , 10-15, Volume: 25, Issue:20, 2017
Functionally selective dopamine D₂, D₃ receptor partial agonists.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.Bioorganic & medicinal chemistry, , 05-15, Volume: 27, Issue:10, 2019
Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors.Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013
Synthesis of potent and selective serotonin 5-HT1B receptor ligands.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 15, Issue:21, 2005
Evolution of a novel series of [(N,N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists.Journal of medicinal chemistry, , Jul-22, Volume: 37, Issue:15, 1994
[no title available]Bioorganic & medicinal chemistry letters, , 11-01, Volume: 30, Issue:21, 2020
Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 20, Issue:3, 2010
Remote functionalization of SCH 39166: discovery of potent and selective benzazepine dopamine D1 receptor antagonists.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 20, Issue:3, 2010
A study on the contribution of the 1-phenyl substituent to the molecular electrostatic potentials of some benzazepines in relation to selective dopamine D-1 receptor activity.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective DJournal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
A novel synthesis and pharmacological evaluation of a potential dopamine D1/D2 agonist: 1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006
Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist.Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 14, Issue:12, 2004
Return of DJournal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.Bioorganic & medicinal chemistry, , Jul-15, Volume: 17, Issue:14, 2009
Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors.Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.ACS medicinal chemistry letters, , Mar-12, Volume: 11, Issue:3, 2020
Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 ReceptorsACS medicinal chemistry letters, , Mar-10, Volume: 2, Issue:3, 2011
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors.Bioorganic & medicinal chemistry letters, , 03-15, Volume: 27, Issue:6, 2017
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013
Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.Bioorganic & medicinal chemistry letters, , 08-15, Volume: 30, Issue:16, 2020
Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.ACS medicinal chemistry letters, , Mar-12, Volume: 11, Issue:3, 2020
Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.Bioorganic & medicinal chemistry, , 05-15, Volume: 27, Issue:10, 2019
Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 25, Issue:18, 2015
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 23, Issue:6, 2013
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.Bioorganic & medicinal chemistry, , Aug-01, Volume: 20, Issue:15, 2012
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.Journal of medicinal chemistry, , Aug-11, Volume: 54, Issue:15, 2011
Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 20, Issue:3, 2010
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: deBioorganic & medicinal chemistry, , Nov-01, Volume: 18, Issue:21, 2010
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.Journal of medicinal chemistry, , Nov-27, Volume: 51, Issue:22, 2008
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines.Bioorganic & medicinal chemistry, , Jul-15, Volume: 16, Issue:14, 2008
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.Journal of medicinal chemistry, , Nov-03, Volume: 48, Issue:22, 2005
A study on the contribution of the 1-phenyl substituent to the molecular electrostatic potentials of some benzazepines in relation to selective dopamine D-1 receptor activity.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
Development of a high affinity and stereoselective photoaffinity label for the D-1 dopamine receptor: synthesis and resolution of 7-[125I]iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro- 1H-3-benzazepine.Journal of medicinal chemistry, , Volume: 33, Issue:2, 1990
Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.Journal of medicinal chemistry, , Volume: 32, Issue:9, 1989
Fancy bioisosteres: novel paracyclophane derivatives as super-affinity dopamine D3 receptor antagonists.Journal of medicinal chemistry, , Jun-15, Volume: 49, Issue:12, 2006
Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002
2-Phenylcyclopropylmethylamine Derivatives as Dopamine DJournal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.ACS medicinal chemistry letters, , Apr-10, Volume: 5, Issue:4, 2014
Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 18, Issue:13, 2008
Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 17, Issue:5, 2007
Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist.Journal of medicinal chemistry, , Mar-23, Volume: 49, Issue:6, 2006
Dopamine/serotonin receptor ligands. 13: Homologization of a benzindoloazecine-type dopamine receptor antagonist modulates the affinities for dopamine D(1)-D(5) receptors.Journal of medicinal chemistry, , Oct-19, Volume: 49, Issue:21, 2006
Return of DJournal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacJournal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.European journal of medicinal chemistry, , Volume: 48, 2012
Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.Bioorganic & medicinal chemistry, , Sep-15, Volume: 19, Issue:18, 2011
Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?Bioorganic & medicinal chemistry, , Oct-01, Volume: 17, Issue:19, 2009
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.Journal of medicinal chemistry, , Nov-16, Volume: 49, Issue:23, 2006
trans-2,6-,3,6- and 4,6-diaza-5,6,6a,7,8,12b-hexahydro-benzo[c]phenanthrene-10,11- diols as dopamine agonists.Bioorganic & medicinal chemistry letters, , May-17, Volume: 9, Issue:10, 1999
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacJournal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.Bioorganic & medicinal chemistry letters, , 08-15, Volume: 30, Issue:16, 2020
Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.ACS medicinal chemistry letters, , Apr-10, Volume: 5, Issue:4, 2014
A novel synthesis and pharmacological evaluation of a potential dopamine D1/D2 agonist: 1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol.Bioorganic & medicinal chemistry, , Mar-15, Volume: 16, Issue:6, 2008
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacJournal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.Journal of medicinal chemistry, , Volume: 33, Issue:8, 1990
Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.Bioorganic & medicinal chemistry, , Nov-01, Volume: 22, Issue:21, 2014
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.Bioorganic & medicinal chemistry, , Feb-15, Volume: 21, Issue:4, 2013
Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.Bioorganic & medicinal chemistry, , Aug-01, Volume: 20, Issue:15, 2012
Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?Bioorganic & medicinal chemistry, , Oct-01, Volume: 17, Issue:19, 2009
trans-2,6-,3,6- and 4,6-diaza-5,6,6a,7,8,12b-hexahydro-benzo[c]phenanthrene-10,11- diols as dopamine agonists.Bioorganic & medicinal chemistry letters, , May-17, Volume: 9, Issue:10, 1999
(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacJournal of medicinal chemistry, , Sep-01, Volume: 38, Issue:18, 1995
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.Journal of medicinal chemistry, , Apr-23, Volume: 52, Issue:8, 2009
Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002
Return of DJournal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.Journal of medicinal chemistry, , Apr-23, Volume: 52, Issue:8, 2009
Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.Journal of medicinal chemistry, , Oct-10, Volume: 45, Issue:21, 2002
Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D2 ReceptorsACS medicinal chemistry letters, , Mar-10, Volume: 2, Issue:3, 2011
Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands.Bioorganic & medicinal chemistry, , Sep-15, Volume: 16, Issue:18, 2008
Return of DJournal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017
Return of DJournal of medicinal chemistry, , 09-14, Volume: 60, Issue:17, 2017
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.Journal of medicinal chemistry, , Feb-16, Volume: 39, Issue:4, 1996
2-Phenylcyclopropylmethylamine Derivatives as Dopamine DJournal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Development of molecular tools based on the dopamine DBioorganic & medicinal chemistry, , 07-01, Volume: 25, Issue:13, 2017
Functionally selective dopamine D₂, D₃ receptor partial agonists.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?Bioorganic & medicinal chemistry, , Oct-01, Volume: 17, Issue:19, 2009
Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 18, Issue:13, 2008
Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 17, Issue:5, 2007
Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist.Journal of medicinal chemistry, , Mar-23, Volume: 49, Issue:6, 2006
Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.Journal of medicinal chemistry, , Feb-14, Volume: 51, Issue:3, 2008
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.Proceedings of the National Academy of Sciences of the United States of America, , May-15, Volume: 104, Issue:20, 2007
Identification of 2-fluoro-8-methyl-11-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine with clozapine-like mixed activities at muscarinic acetylcholine, dopamine, and serotonin receptors.Bioorganic & medicinal chemistry letters, , 05-15, Volume: 40, 2021
[no title available]Bioorganic & medicinal chemistry letters, , 11-01, Volume: 30, Issue:21, 2020
Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 19, Issue:2, 2009
Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 19, Issue:21, 2009
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Hydrazides of clozapine: a new class of D1 dopamine receptor subtype selective antagonists.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 16, Issue:17, 2006
Modification of the clozapine structure by parallel synthesis.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 16, Issue:17, 2006
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential.Bioorganic & medicinal chemistry letters, , Aug-16, Volume: 14, Issue:16, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.Journal of medicinal chemistry, , Jul-05, Volume: 39, Issue:14, 1996
Synthesis and evaluation of novel alkylpiperazines as potential dopamine antagonists.Journal of medicinal chemistry, , Volume: 24, Issue:6, 1981
[no title available],
[no title available]Bioorganic & medicinal chemistry letters, , 11-01, Volume: 30, Issue:21, 2020
Further evaluation of the tropane analogs of haloperidol.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 24, Issue:17, 2014
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
[no title available],
Identification of 2-fluoro-8-methyl-11-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine with clozapine-like mixed activities at muscarinic acetylcholine, dopamine, and serotonin receptors.Bioorganic & medicinal chemistry letters, , 05-15, Volume: 40, 2021
Enables
This protein enables 8 target(s):
| Target | Category | Definition |
|---|
| dopamine neurotransmitter receptor activity, coupled via Gs | molecular function | Combining with the neurotransmitter dopamine and activating adenylate cyclase via coupling to Gs to initiate a change in cell activity. [GOC:mah, ISBN:0953351033, IUPHAR_RECEPTOR:2252, IUPHAR_RECEPTOR:2260] |
| G-protein alpha-subunit binding | molecular function | Binding to a G-protein alpha subunit. The alpha subunit binds a guanine nucleotide. [GOC:hjd] |
| dopamine neurotransmitter receptor activity | molecular function | Combining with the neurotransmitter dopamine to initiate a change in cell activity. [GOC:PARL, IUPHAR_GPCR:1282, PMID:21711983] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| heterotrimeric G-protein binding | molecular function | Binding to a heterotrimeric G-protein. [GOC:nln] |
| dopamine binding | molecular function | Binding to dopamine, a catecholamine neurotransmitter formed by aromatic-L-amino-acid decarboxylase from 3,4-dihydroxy-L-phenylalanine. [ISBN:0198506732] |
| arrestin family protein binding | molecular function | Binding to a member of the arrestin family, proteins involved in agonist-mediated desensitization of G protein-coupled receptors. [PMID:23911909] |
| G protein-coupled receptor activity | molecular function | Combining with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. [GOC:bf, http://www.iuphar-db.org, Wikipedia:GPCR] |
Located In
This protein is located in 11 target(s):
| Target | Category | Definition |
|---|
| nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
| endoplasmic reticulum membrane | cellular component | The lipid bilayer surrounding the endoplasmic reticulum. [GOC:mah] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| cilium | cellular component | A specialized eukaryotic organelle that consists of a filiform extrusion of the cell surface and of some cytoplasmic parts. Each cilium is largely bounded by an extrusion of the cytoplasmic (plasma) membrane, and contains a regular longitudinal array of microtubules, anchored to a basal body. [GOC:cilia, GOC:curators, GOC:kmv, GOC:vw, ISBN:0198547684, PMID:16824949, PMID:17009929, PMID:20144998] |
| presynaptic membrane | cellular component | A specialized area of membrane of the axon terminal that faces the plasma membrane of the neuron or muscle fiber with which the axon terminal establishes a synaptic junction; many synaptic junctions exhibit structural presynaptic characteristics, such as conical, electron-dense internal protrusions, that distinguish it from the remainder of the axon plasma membrane. [GOC:jl, ISBN:0815316194] |
| dendritic spine | cellular component | A small, membranous protrusion from a dendrite that forms a postsynaptic compartment, typically receiving input from a single presynapse. They function as partially isolated biochemical and an electrical compartments. Spine morphology is variable:they can be thin, stubby, mushroom, or branched, with a continuum of intermediate morphologies. They typically terminate in a bulb shape, linked to the dendritic shaft by a restriction. Spine remodeling is though to be involved in synaptic plasticity. [GOC:nln] |
| postsynaptic membrane | cellular component | A specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft). Neurotransmitters cross the synaptic cleft and transmit the signal to the postsynaptic membrane. [ISBN:0198506732] |
| ciliary membrane | cellular component | The portion of the plasma membrane surrounding a cilium. [GOC:cilia, GOC:dph, GOC:rph] |
| non-motile cilium | cellular component | A cilium which may have a variable array of axonemal microtubules but does not contain molecular motors. [GOC:cilia, GOC:dgh, GOC:kmv, PMID:17009929, PMID:20144998, PMID:22118931] |
| glutamatergic synapse | cellular component | A synapse that uses glutamate as a neurotransmitter. [GOC:dos] |
| GABA-ergic synapse | cellular component | A synapse that uses GABA as a neurotransmitter. These synapses are typically inhibitory. [GOC:dos] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Part Of
This protein is part of 1 target(s):
| Target | Category | Definition |
|---|
| G protein-coupled receptor complex | cellular component | A protein complex that contains G protein-coupled receptors. [GOC:bhm] |
Involved In
This protein is involved in 52 target(s):
| Target | Category | Definition |
|---|
| temperature homeostasis | biological process | A homeostatic process in which an organism modulates its internal body temperature. [GOC:jl] |
| conditioned taste aversion | biological process | A conditioned aversion to a specific chemical compound as a result of that compound being coupled with a noxious stimulus. [GOC:dph, PMID:9920659] |
| behavioral fear response | biological process | An acute behavioral change resulting from a perceived external threat. [GOC:dph, PMID:9920659] |
| regulation of protein phosphorylation | biological process | Any process that modulates the frequency, rate or extent of addition of phosphate groups into an amino acid in a protein. [GOC:hjd] |
| synaptic transmission, dopaminergic | biological process | The vesicular release of dopamine. from a presynapse, across a chemical synapse, the subsequent activation of dopamine receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:dos, GOC:dph] |
| response to amphetamine | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amphetamine stimulus. Amphetamines consist of a group of compounds related to alpha-methylphenethylamine. [GOC:dph, GOC:ef] |
| protein import into nucleus | biological process | The directed movement of a protein from the cytoplasm to the nucleus. [GOC:jl] |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | biological process | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation or inhibition of a nucleotide cyclase activity and a subsequent change in the concentration of a cyclic nucleotide. [GOC:mah, GOC:signaling, ISBN:0815316194] |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | biological process | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of adenylyl cyclase activity which results in an increase in the intracellular concentration of cyclic AMP (cAMP). This pathway is negatively regulated by phosphodiesterase, which cleaves cAMP and terminates the signaling. [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194] |
| activation of adenylate cyclase activity | biological process | Any process that initiates the activity of the inactive enzyme adenylate cyclase. [GOC:ai] |
| adenylate cyclase-activating dopamine receptor signaling pathway | biological process | An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor, and ending with the regulation of a downstream cellular process. [GOC:mah, GOC:signaling] |
| synapse assembly | biological process | The aggregation, arrangement and bonding together of a set of components to form a synapse. This process ends when the synapse is mature (functional). [GOC:mah] |
| memory | biological process | The activities involved in the mental information processing system that receives (registers), modifies, stores, and retrieves informational stimuli. The main stages involved in the formation and retrieval of memory are encoding (processing of received information by acquisition), storage (building a permanent record of received information as a result of consolidation) and retrieval (calling back the stored information and use it in a suitable way to execute a given task). [GOC:curators, ISBN:0582227089] |
| mating behavior | biological process | The behavioral interactions between organisms for the purpose of mating, or sexual reproduction resulting in the formation of zygotes. [GOC:ai, GOC:dph] |
| grooming behavior | biological process | The specific behavior of an organism relating to grooming, cleaning and brushing to remove dirt and parasites. [GOC:jl, GOC:pr] |
| adult walking behavior | biological process | The behavior of an adult relating to the progression of that organism along the ground by the process of lifting and setting down each leg. [GOC:jid, GOC:pr, ISBN:0198606907] |
| visual learning | biological process | Any process in an organism in which a change in behavior of an individual occurs in response to repeated exposure to a visual cue. [GOC:jid, ISBN:0582227089] |
| response to xenobiotic stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
| astrocyte development | biological process | The process aimed at the progression of an astrocyte over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell. An astrocyte is the most abundant type of glial cell. Astrocytes provide support for neurons and regulate the environment in which they function. [GOC:dgh, GOC:ef] |
| dopamine transport | biological process | The directed movement of dopamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Dopamine is a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline. [GOC:ai] |
| transmission of nerve impulse | biological process | The neurological system process in which a signal is transmitted through the nervous system by a combination of action potential propagation and synaptic transmission. [GOC:curators, ISBN:0815316194] |
| neuronal action potential | biological process | An action potential that occurs in a neuron. [GOC:dph, GOC:isa_complete, GOC:tb] |
| dentate gyrus development | biological process | The process whose specific outcome is the progression of the dentate gyrus over time, from its formation to the mature structure. The dentate gyrus is one of two interlocking gyri of the hippocampus. It contains granule cells, which project to the pyramidal cells and interneurons of the CA3 region of the ammon gyrus. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343] |
| striatum development | biological process | The progression of the striatum over time from its initial formation until its mature state. The striatum is a region of the forebrain consisting of the caudate nucleus, putamen and fundus striati. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0878937420] |
| cerebral cortex GABAergic interneuron migration | biological process | The migration of GABAergic interneuron precursors from the subpallium to the cerebral cortex. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695] |
| positive regulation of cell migration | biological process | Any process that activates or increases the frequency, rate or extent of cell migration. [GOC:go_curators] |
| peristalsis | biological process | A wavelike sequence of involuntary muscular contraction and relaxation that passes along a tubelike structure, such as the intestine, impelling the contents onwards. [ISBN:0198506732] |
| operant conditioning | biological process | Learning to anticipate future events on the basis of past experience with the consequences of one's own behavior. [PMID:14662373] |
| synaptic transmission, glutamatergic | biological process | The vesicular release of glutamate from a presynapse, across a chemical synapse, the subsequent activation of glutamate receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:dos] |
| regulation of dopamine metabolic process | biological process | Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving dopamine. [GOC:go_curators] |
| vasodilation | biological process | An increase in the internal diameter of blood vessels, especially arterioles or capillaries, due to relaxation of smooth muscle cells that line the vessels, and usually resulting in a decrease in blood pressure. [GOC:pr, ISBN:0192800981] |
| dopamine metabolic process | biological process | The chemical reactions and pathways involving dopamine, a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline. [GOC:jl, ISBN:0198506732] |
| maternal behavior | biological process | Female behaviors associated with the care and rearing of offspring. [GOC:curators] |
| positive regulation of potassium ion transport | biological process | Any process that activates or increases the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. [GOC:jl] |
| glucose import | biological process | The directed movement of the hexose monosaccharide glucose into a cell or organelle. [GOC:ai] |
| habituation | biological process | A decrease in a behavioral response to a repeated stimulus. This is exemplified by the failure of a person to show a startle response to a loud noise that has been repeatedly presented. [ISBN:0582227089] |
| sensitization | biological process | An increased in a behavioral response to a repeated stimulus. For example, a shock to the tail of the marine snail Aplysia, to which the snail responds by withdrawing its gill, will result in increased gill withdrawal the next time the skin is touched. [ISBN:0582227089] |
| behavioral response to cocaine | biological process | Any process that results in a change in the behavior of an organism as a result of a cocaine stimulus. [GOC:jid] |
| positive regulation of release of sequestered calcium ion into cytosol | biological process | Any process that activates or increases the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria. [GOC:ai] |
| regulation of dopamine uptake involved in synaptic transmission | biological process | Any process that modulates the frequency, rate or extent of the directed movement of the catecholamine neurotransmitter dopamine into a cell. [GOC:ai] |
| positive regulation of synaptic transmission, glutamatergic | biological process | Any process that activates, maintains or increases the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate. [GOC:ai] |
| prepulse inhibition | biological process | The process in which a startle magnitude is reduced when the startling stimulus is preceded by a low-intensity prepulse. [GOC:dph, PMID:10341260] |
| phospholipase C-activating dopamine receptor signaling pathway | biological process | A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:dph, GOC:signaling, GOC:tb, PMID:12675914] |
| long-term synaptic potentiation | biological process | A process that modulates synaptic plasticity such that synapses are changed resulting in the increase in the rate, or frequency of synaptic transmission at the synapse. [GOC:dgh, GOC:dph] |
| long-term synaptic depression | biological process | A process that modulates synaptic plasticity such that synapses are changed resulting in the decrease in the rate, or frequency of synaptic transmission at the synapse. [GOC:dgh, GOC:dph] |
| cellular response to catecholamine stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a catecholamine stimulus. A catecholamine is any of a group of biogenic amines that includes 4-(2-aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] and derivatives formed by substitution. [GOC:BHF, GOC:mah] |
| modification of postsynaptic structure | biological process | Any process that modifies the structure of a postsynapse. [GOC:dos] |
| presynaptic modulation of chemical synaptic transmission | biological process | Any process, acting in the presynapse that results in modulation of chemical synaptic transmission. [GOC:dos] |
| positive regulation of neuron migration | biological process | Any process that activates or increases the frequency, rate or extent of neuron migration. [GOC:obol] |
| positive regulation of MAPK cascade | biological process | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade. [GOC:go_curators] |
| adenylate cyclase-activating adrenergic receptor signaling pathway | biological process | An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process. [GOC:BHF, GOC:mah, GOC:signaling] |
| dopamine receptor signaling pathway | biological process | The series of molecular signals generated as a consequence of a dopamine receptor binding to one of its physiological ligands. [GOC:mah, PMID:21711983] |